Corbus Pharmaceuticals Holdings, Inc. (CRBP)
Trading disclosure
The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for certain activity generated through this link. Prices displayed are informational.
Learn moreKey Executives
| Name | Title | Pay | Exercised | Year Born |
|---|---|---|---|---|
|
Dr. Yuval Cohen Ph.D.
|
CEO & Director | 1.04M | -- | 1975 |
|
Mr. Sean F. Moran CPA, M.B.A.
|
Chief Financial Officer | 695.75k | -- | 1958 |
|
Dr. Ian Hodgson B.Sc., Ph.D.
|
Chief Operating Officer | -- | -- | 1973 |
|
Mr. G. Scott Goeken J.D., M.S.
|
General Counsel & Corporate Secretary | -- | -- | -- |
|
Ms. Christina Bertsch M.A.
|
Vice President of Human Resources | -- | -- | -- |
|
Mr. Nishant C. Saxena
|
Chief Business Officer | -- | -- | -- |
|
Dr. Leonardo Viana Nicacio M.D.
|
Chief Medical Officer | -- | -- | 1978 |
Corbus Pharmaceuticals Holdings, Inc.
- Sector:
- Healthcare
- Industry: Biotechnology
- Full Time Employees:
- 36
Description
Corbus Pharmaceuticals Holdings, Inc., a clinical stage company, develops and commercializes therapeutics for cancer and obesity. Its pipeline includes CRB-701, an antibody drug conjugate that targets the expression of Nectin-4 on cancer cells to release a cytotoxic payload of monomethyl auristatin E; and CRB-913, a peripherally restricted cannabinoid type-1 receptor inverse agonist for the treatment of obesity. The company was incorporated in 2009 and is headquartered in Norwood, Massachusetts.
Corporate Governance
Upcoming Events
November 16, 2026 at 1:30 PM UTC
Corbus Pharmaceuticals Holdings, Inc. Earnings Date
